AJP Asia Intelligence Agency

Biohealth Industry Drives Cosmetic Growth as Pharmaceutical Firms Seek New Avenues

The cosmetics sector is leading the growth of the biohealth industry, fueled by the K-beauty trend. In contrast, mid-sized and small pharmaceutical companies, which rely heavily on reimbursable drugs, are struggling with declining profitability due to pressure from price cuts. This is why pharmaceutical firms are seeking new breakthroughs in the dermacosmetic business.

According to the '2026 Q2 Biohealth Industry Business Management Analysis' released on the 22nd by the Korea Health Industry Development Institute, the revenue of 328 domestic biohealth manufacturers in the second quarter of this year reached 17.39 trillion won (KRW), a 12.9% increase from 15.4 trillion won (KRW) during the same period last year. The revenue growth rate rose by 0.3 percentage points from 12.6% in the first quarter.

The fastest-growing sector was cosmetics. Cosmetics companies reported second-quarter revenues of 4.55 trillion won (KRW), marking a 24.1% increase compared to the same period last year. This growth rate is 8.4 percentage points higher than the 15.7% recorded in the first quarter. Notably, mid-sized cosmetics firms saw a revenue growth rate of 34.1%, up 6.0 percentage points from 28.1% in the first quarter. Small businesses also recorded a high growth rate of 24.2%. The expansion of K-beauty sales overseas and a recovery in consumption focused on high-functionality and premium products are believed to support this growth.

In contrast, the revenue growth rate for pharmaceutical companies dropped from 12.4% to 7.3%, a decline of 5.1 percentage points during the same period. In fact, several pharmaceutical companies have seen their operating profits decline despite an increase in revenue in the third quarter of this year. Hanmi Pharmaceutical reported a 4.2% increase in third-quarter revenue to 377.4 billion won (KRW) compared to the same period last year, but its operating profit fell by 31.3% to 37.8 billion won (KRW). Boryung saw a 12.3% increase in revenue, yet its operating profit decreased by 13.4% to 25.4 billion won (KRW). Likewise, Kwangdong Pharmaceutical's revenue rose to 460.6 billion won (KRW), but its operating profit dropped by 35.2% to 7 billion won (KRW).

Starting next year, the burden of drug pricing is expected to increase further. The government plans to implement price cuts starting in April next year as part of the first phase of re-evaluation, with the second phase beginning in October 2030 and concluding by October 2036 at the latest. As a result, general pharmaceutical companies will face additional pressure for price reductions starting next year. Mid-sized and small pharmaceutical firms, which have a high proportion of generic sales, are likely to be hit hardest by this structure.

Consequently, pharmaceutical companies are increasing their focus on non-reimbursable businesses such as cosmetics and health supplements. Dongkook Pharmaceutical has entered approximately 7,500 offline stores in Japan with its dermacosmetic brand 'Centellian24,' which utilizes the wound treatment ingredient madecassoside. In the third quarter, it also expanded into the offline stores of the UK health and beauty retailer Boots, targeting the European market. Dongkook Pharmaceutical's cumulative consolidated revenue for the first three quarters of this year reached 768.6 billion won (KRW), a 12.4% increase from the same period last year. Its operating profit also rose by 6.9% to 77.2 billion won (KRW).

Hanmi Science is expanding its product line for the dermacosmetic brand 'Adesi' and broadening its sales channels in dermatology. Other companies like Dong-A Pharmaceutical's 'Partion' and Daewoong Pharmaceutical's 'Easydew' are also actively pursuing domestic and international market strategies.

An industry insider stated, "As it becomes increasingly difficult to secure continuous growth and profitability with only reimbursable drugs, there is a trend to increase the share of non-reimbursable businesses. In the highly competitive aesthetic market, having differentiated products and a global sales network is essential for translating efforts into results."





* This article has been translated by AI.